Dr. Brendan H. Mccann, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 8 Hill Way Ste A, Cape Elizabeth, ME 04107 Phone: 207-799-9950 Fax: 207-799-9951 |
Erik William Metzger, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 8 Hill Way Ste A, Cape Elizabeth, ME 04107 Phone: 207-799-9950 Fax: 207-799-9951 |
Mainely Chiropractic Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 1000 Shore Rd, Bldg. 326, Cape Elizabeth, ME 04107 Phone: 207-650-2493 |
Dr. Zev Myerowitz Jr., D.C., L.AC Chiropractor - Sports Physician Medicare: Accepting Medicare Assignments Practice Location: 8 Hill Way Ste A, Cape Elizabeth, ME 04107 Phone: 207-799-9950 Fax: 207-799-9951 |
Benjamin Allen Rogers, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 8 Hill Way Unit 10, Cape Elizabeth, ME 04107 Phone: 207-799-9950 Fax: 207-799-9951 |
Cape Chiropractic And Acupuncture Chiropractor Medicare: Medicare Enrolled Practice Location: 8 Hill Way Ste A, Cape Elizabeth, ME 04107 Phone: 207-799-9950 Fax: 207-799-9951 |
Dr. Kyle Roland Neagle, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 2 Davis Point Ln, Cape Elizabeth, ME 04107 Phone: 207-799-9950 |
News Archive
EDAP TMS SA, the global leader in therapeutic ultrasound, announced today the European approval of its new lithotripter, the Sonolith i-move. The EDAP sales team and distributors will begin marketing Sonolith i-move immediately and will officially introduce the product to distributors, partners and visiting urologists at the European Association Urology (EAU) congress, Booth #14, from April 17-19, 2010 in Barcelona, Spain.
From today, patients with a very aggressive form of breast cancer known as HER2-positive, could benefit from a new faster, more efficient delivery method of Herceptin. The subcutaneous injection, given just beneath the skin, can be completed in 2-5 minutes, compared to the traditional, relatively time-consuming 30-90 minute intravenous infusion.
A study recently published in Scientific Reports discovered that 65% of Lyme disease patients irrespective of their disease stage respond to several microbes.
Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference "Advances in Molecular Mechanisms of Atherosclerosis" being held in Banff, Alberta, Canada. Idera's proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.
› Verified 8 days ago